AlphAIAlphAI — Financial news for AI agents
orthospinenews.comOCT 212 min read$IART

Integra LifeSciences Reports Third Quarter 2026 Financial Results – Ortho Spine News

Integra LifeSciences (IART) reported Q3 2026 revenues of $411.2M, up 2.3%. GAAP EPS was $0.19, adjusted EPS $0.59. The company cited $7M revenue impact from flood damage and softer Tissue Reconstruction results. Full-year guidance remains unchanged at $1.634B-$1.654B revenue and $2.30-$2.40 adjusted EPS. Post-quarter, IART completed a $2.1B debt refinancing.

Original reporting
orthospinenews.com
Published Oct 21, 2026, 7:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Integra LifeSciences Reports Third Quarter 2026 Financial Results – Ortho Spine News — source image
Source · orthospinenews.com
Decision brief

The 30-second read

$IARTNeutralHigh
01

Why it matters

The Q3 earnings beat and $2.1 B refinancing provide fresh data for valuation models; guidance remains flat, suggesting limited upside beyond the earnings surprise.

02

Market read

First‑report earnings and financing news deliver actionable information for traders focused on med‑tech equities.

03

What to watch

Potential flood‑related disruptions at the Cincinnati facility may recur, and tissue‑reconstruction segment showed revenue decline.

Relevance 8/10Novelty 8/10Timing: immediate today

Background

Integra LifeSciences (IART) is a Nasdaq‑listed medical‑technology company providing specialty surgical and tissue‑reconstruction products.

Company-level read

Ticker impact

$IARTNeutralHigh confidence
Context

Integra LifeSciences reported Q3 2026 results, posted GAAP EPS $0.19, adjusted EPS $0.59, and announced a $2.1 billion debt refinancing with updated guidance.

Expected impact

moderate upside as market prices in stronger cash flow and refined leverage profile

Evidence & confidence

Positive earnings surprise and a large refinancing tranche signal financial flexibility, but mixed revenue growth and higher interest costs temper enthusiasm.

Market effects

Sector

Medical‑technology sector may see slight uplift from Integra's improved leverage and cash flow trends.

Regional

U.S. healthcare equities could experience modest buying pressure.

Global

Limited to U.S. and global med‑tech investors; no broad macro effect.

Counterpoint

What could challenge this read

Higher interest expense from the new notes could pressure margins, leading to a muted or negative reaction.

Key entities

  • Executive
    Stuart Essig

    Chairman and CEO of Integra LifeSciences, quoted on results and outlook.

Read at source← All news

StoryIntegra LifeSciences reports Q3 2026 earnings, cites flood impact and revises Q4 outlook

Also covered by

6 outlets

Related articles

OCT 21
$IARTMed

Integra LifeSciences (IART) Reports Q3 Revenue In Line with Guid

Integra LifeSciences (IART) reported Q3 revenue of $411M, meeting the lower end of its guidance. The company lowered its full-year revenue outlook by $30M due to operational disruptions. IART's P/S ratio is 0.57, below historical and industry averages. The company has a GF Score of 69, indicating mixed fundamentals with strengths in momentum and profitability but weaknesses in growth and financial strength. Insider activity shows net buying of $0.1M, while institutional interest is mixed.

gurufocus.com3 min
OCT 21
$IARTHighAI 8/10

Integra (IART) Q3 2026 Earnings Call Transcript

Integra (IART) reported Q3 2026 adjusted EPS of $0.59, with revenue at $411.2M, impacted by Cincinnati flooding. Operating cash flow was $96M. Full-year revenue guidance was reduced by $30M due to flooding and mixed portfolio performance. Tissue Reconstruction revenue is expected to be flat. The company reduced leverage to 3.8x and completed debt refinancing, strengthening its balance sheet.

finance.yahoo.com3 min
OCT 21
$IARTHigh

Integra Life falls as tissue reconstruction woes add to flooding worries in Q3

Integra LifeSciences (IART) shares fell to a May low after Q3 2026 results missed revenue estimates. Revenue was $411.2M, up 2% YoY but below consensus by $0.9M, impacted by a $7M headwind and weaker Tissue Reconstruction performance. Gross margin declined 500 bps to 51%, while adjusted net income rose 12% YoY to $46.4M, beating estimates by $0.03 per share. Q4 and full-year outlooks were set below consensus.

tradingview.com2 min
OCT 21
Med

Integra LifeSciences Holdings Corporation Q3 2026 Earnings Call Summary

Integra LifeSciences reported Q3 2026 earnings, citing a $7M revenue hit from Cincinnati flooding. Neurosurgery grew 6.5% organically, offsetting weaker segments. Tissue Reconstruction showed mixed results. The company refinanced $2.1B in debt. Management expects 2027 revenue to be impacted by $15M-$20M in Q1 and Q2 due to ongoing disruption. Earnings growth is projected to be supported by cost savings and a SurgiMend relaunch.

finance.yahoo.com2 min
OCT 21
$IARTMed

Why Integra LifeSciences (IART) stock is falling today

Integra LifeSciences (IART) shares fell 7.3% after reporting Q3 revenue of $411.2M, meeting expectations, and adjusted EPS of $0.59, beating estimates. The company cited plant flooding and operational disruptions, projecting Q4 revenue of $413M-$433M, below analyst estimates of $433.2M. Rising borrowing costs also weighed on investor sentiment.

financialcontent.com2 min